InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR... Show more
The 50-day moving average for IFRX moved below the 200-day moving average on April 01, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on March 28, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IFRX as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IFRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IFRX entered a downward trend on April 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IFRX's RSI Indicator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for IFRX just turned positive on March 14, 2025. Looking at past instances where IFRX's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IFRX advanced for three days, in of 215 cases, the price rose further within the following month. The odds of a continued upward trend are .
IFRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.162) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (384.615) is also within normal values, averaging (252.036).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IFRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IFRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
a developer of biopharmaceutical products
Industry Biotechnology
A.I.dvisor tells us that IFRX and NNVC have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IFRX and NNVC's prices will move in lockstep.
Ticker / NAME | Correlation To IFRX | 1D Price Change % | ||
---|---|---|---|---|
IFRX | 100% | +9.52% | ||
NNVC - IFRX | 30% Poorly correlated | -0.86% | ||
TNGX - IFRX | 28% Poorly correlated | +7.03% | ||
ALLO - IFRX | 28% Poorly correlated | +5.11% | ||
VERA - IFRX | 27% Poorly correlated | +7.13% | ||
SPRB - IFRX | 27% Poorly correlated | +9.21% | ||
More |